IP Library Granted Patent US 8,252,928
Granted Patent B2
US 8,252,928 · App. 12/558,646 · Granted Aug 28, 2012

Processes for the synthesis of five and six membered heterocyclic rings

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,252,928
App. No.
12/558,646
Granted
Aug 28, 2012
Kind
B2
Abstract

The present invention provides processes for the synthesis of five and six membered rings. In particular, the present invention provides processes for the synthesis of five and six membered rings in alkaloids.

Claims (44)

1. A process for the preparation of a compound of Formula (IIa):

the process comprising:

(a) contacting a compound of Formula (Ia), with an alcohol and a proton donor having a pKA of less than 0 to form a reaction mixture, wherein a molar ratio of the proton donor to compound of Formula (Ia) is from about 1:1 to about 20:1, and wherein the compound of Formula (Ia) is of the following structure:

(b) heating the reaction mixture to form a compound of Formula (IIa), wherein:

A is {—}O{—} and is a member of a five-membered heterocyclic ring;

R 1 , R 2 , and R 3 are each independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, {—}OH, {—}NH 2 , {—}SH, {—}SR 111 , {—}OR 111 , and {—}N(R 111 ) 2 ;

R 4 is selected from the group consisting of {—}OH, {—}SH, {—}NH 2 , {—}NHR 112 , {—}N(OH)R 112 , {—}P(OH) 2 , {—]P(OH)R 112 , {—}B(OH) 2 , {—}B(OH)R 112 , and {—}Si(OH)(R 112 ) 2 ;

R 5 , R 6a , R 6b , R 7a , R 7b , R 8a , and R 8b , are each independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, {—}OH, {—}NH 2 , {—}SH, {—}SR 111 , {—}OR 111 , and {—}N(R 111 ) 2 ; provided that any of R 6a and R 6b , R 7a and R 7b , R 8a and R 8b , may together form a moiety selected from the group consisting of {═}O, {═}S, and {═}NR 111 ;

R 9 , R 10a , R 10b , R I4 , R I5a , R I5b , R I6a , R I6b , and R I7 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and {—}OR 112 ;

R 111 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 112 is selected from the group consisting of {—}H, hydrocarbyl, and substituted hydrocarbyl; and

carbons attached to R groups selected from the group consisting of R 5 , R 6a , R 6b , R 7a , R 7b , R 8a , R 8b , R 10a , R 10b , R 15a , R 15b , R 16a , and R 16b may optionally form a carbon-carbon double bond with each other or an adjacent carbon.

2. The process of claim 1 , wherein the reaction mixture further comprises an aprotic solvent and a water scavenger, the alcohol comprises an alkoxy, and the reaction mixture is heated to a temperature of about 20° C. to about 120° C.

3. The process of claim 1 , wherein the reaction mixture is heated to a temperature of about 20° C. to about 120° C. for a period of time sufficient to convert a substantial portion of the compound having Formula (Ia) to a mixture of intermediates comprising ketal derivatives.

4. The process of claim 3 , wherein the ketal derivative comprises a moiety or ring structure selected from the group of compounds of any of Formulas (III), (IIIb), (IIIc), and (IIId):

wherein:

B is selected from the group consisting of halogen, {—}OH, {—}OR 20 , {—}SH, and {—}SR 20 ;

R 20 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl; and

R 516 and R 517 are independently selected from the group consisting of {—}OH, {—}OR 20 , {—}SH, and {—}SR 20 .

5. The process of claim 3 , wherein the ketal derivative comprises a moiety or ring structure selected from the group of compounds of any of Formulas (IV), (IVa), (IVc), and (IVd):

wherein:

R 518 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl.

6. The process of claim 3 , wherein the reaction mixture is heated to a temperature of about 60° C. to about 120° C. for a period of time sufficient to convert a substantial portion of the mixture of intermediates comprising ketal derivatives to a mixture of intermediates comprising enol ether derivatives.

7. The process of claim 6 , wherein the enol ether derivative comprises a moiety or ring structure selected from the group of compounds of any of Formulas (V), (Va), (Vb), (Vc), (Vd), (VI), (VIa), (VIb), (VIc), and (VId):

wherein:

B is selected from the group consisting of halogen, {—}OH, {—}OR20, {—}SH, and {—}SR21;

R 21 is selected from the group consisting of {—}H, hydrocarbyl, and substituted hydrocarbyl;

R 514 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl; and

R 515 is selected from the group consisting of O, S, and NR 21 .

8. The process of claim 6 , wherein the enol ether derivative comprises a moiety or ring structure selected from the group of compounds of any of Formulas (VII), (VIIa), (VIIb), (VIIc), and (VIId);

wherein:

R 518 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl.

9. The process of claim 6 , wherein the alcohol is removed from the reaction mixture after the formation of the mixture of intermediates comprising enol ether derivatives; and the reaction mixture is maintained at a temperature of about 60° C. to about 120° C. for a period of time sufficient to convert a substantial portion of the mixture of intermediates comprising enol ether derivatives to the compound of Formula (IIa).

10. The process of claim 1 , further comprising subjecting the compound of Formula (IIa) to hydrolysis to form a compound of Formula (VIIIa):

wherein:

A is {—}O{—} and is a member of a five-membered heterocyclic ring;

R 1 , R 2 , and R 3 are each independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, {—}OH, {—}NH 2 , {—}SH, {—}SR 111 , {—}OR 111 , and {—}N(R 111 ) 2 ;

R 5 , R 7a , R 7b , R 8a , and R 8b , are each independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, {—}OH, {—}NH 2 , {—}SH, {—}SR 111 , and {—}(OR 111 , and {—}N(R 111 ) 2 ; provided that any of R 7a and R 7b , R 8a and R 8b , may together form a moiety selected from the group consisting of {═}O, {═}S, and {═}NR 111 ;

R 9 , R 10a , R 10b , R 14 , R 15a , R 15b , R 16a , R 16b , and R 17 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and {—}OR 112 ;

R 111 is selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl;

R 112 is selected from the group consisting of {—}H, hydrocarbyl, and substituted hydrocarbyl; and

carbons attached to R groups selected from the group consisting of R 7a , R 7b , R 8a , R 8b , R 10a , R 10b , R 15a , R 15b , R 16a , and R 16b may optionally form a carbon-carbon double bond with each other or an adjacent carbon.

11. The process of claim 1 , wherein the optical activity of the compound of Formula (IIa) is selected from the group consisting of (+), (−), and combinations of both; and the configuration of the chiral carbons C-5, C-13, C-14, and C-9 of the compound of comprising Formula (IIa) may be selected from the group consisting of RRRR, RRSR, RRRS, RRSS, RSRR, RSSR, RSRS, RSSS, SRRR, SRSR, SRRS, SRSS, SSRR, SSSR, SSRS, and SSSS; provided, however, that the C-15 and the C-16 carbons are both either on the alpha face of the molecule or the beta face of the molecule.

12. The process of claim 1 wherein the weight/weight ratio of alcohol to compound Formula (Ia) is from about 0.5:1 to about 10:1.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →